ImmunoScape is a biotechnology company focused on immunotherapy and leveraging a unique high-dimensional immune profiling platform. We work with BioPharma and academic partners to conduct deep cellular immunoprofiling across different domains, including infectious diseases, vaccines and oncology. Using mass cytometry and proprietary metal-tagged barcoded tetramers, we have the capacity to identify 100's of antigen-specific T cells in a single sample whilst simultaneously looking at 35+ phenotypic markers.
ImmunoScape is working extensively in the COVID-19 space (i) assessing vaccine-induced immunity to COVID-19 vaccines, (ii) deeply characterizing SARS-CoV-2-specific T cell responses in COVID-19 patients, and (iii) assessing the evolution of immunity in COVID-19 patients on treatment regimens. We have set up a panel of 400 SARS-CoV-2 epitopes and a 30-marker CyOTF panel to screen and characterize epitope usage and the associated cellular phenotype in COVID-19 patients.
To help vaccine development companies assess their COVID-19 vaccine candidates, ImmuoScape tailors it's analytical strategy to analyze the magnitude and quality of the relevant vaccine-induced immune response over time.